Evidence map›Paper›PMID 41388752›Full record

ArticlePediatric hematology and oncology2026

Trends in HU utilization and cerebrovascular outcomes before and after publication of the 2014 National Heart, Lung, and Blood Institute sickle cell disease guidelines.

Aleksandra S Dain, Yimei Li, Sahal Master, Charles L Bailey, Arastoo Vossough, Rebecca N Ichord, Leslie Raffini, Kelly Getz, Janet L Kwiatkowski

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pediatric hematology and oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Aleksandra S DainDivision of Hematology, Children's Hospital of Philadelphia, Department of Pediatrics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.
Yimei LiDivision of Oncology, Children's Hospital of Philadelphia, Philadelphia, PA, USA.
Sahal MasterApplied Clinical Research Center, Roberts Center for Pediatric Research, Children's Hospital of Philadelphia, Philadelphia, PA, USA.
Charles L BaileyDivision of Oncology, Children's Hospital of Philadelphia, Philadelphia, PA, USA.
Arastoo VossoughDivision of Radiology, Children's Hospital of Philadelphia, Department of Radiology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.
Rebecca N IchordDepartments of Neurology and Pediatrics, Division of Neurology, Children's Hospital of Philadelphia, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.
Leslie RaffiniDivision of Hematology, Children's Hospital of Philadelphia, Department of Pediatrics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.
Kelly GetzDivision of Oncology, Children's Hospital of Philadelphia, Philadelphia, PA, USA.
Janet L KwiatkowskiDivision of Hematology, Children's Hospital of Philadelphia, Department of Pediatrics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.

Funding

RED CELL HEMOGLOBIN RESEARCH TRAINING PROGRAMT32HL007150 · NHLBI · CHILDREN'S HOSP OF PHILADELPHIA · PI STELLA T CHOU, Mortimer Poncz · 1985 to 2026
$7.4M
Early Treatment-Related Cardiotoxicity and Subsequent Outcomes in Pediatric Acute Myeloid Leukemia: an Assessment of Development, Progression and MitigationK01HL143153 · NHLBI · UNIVERSITY OF PENNSYLVANIA · PI GETZ, KELLY DIRINGER · 2018 to 2022
$716k
NHLBI NIH HHS K01 HL143153NHLBI NIH HHS T32 HL007150
6 · The paper itself

Abstract

The 2014 National Heart, Lung, and Blood Institute (NHLBI) guidelines recommend offering hydroxyurea to all patients with sickle cell disease SS/Sβ0 (SCD) aged ≥ 9 months. The relationship between early hydroxyurea initiation and the development of cerebrovascular disease (CVD) is unclear. This retrospective study describes trends in HU prescriptions and CVD outcomes in patients with SCD SS/Sβ

Indexed as

Anemia, Sickle CellAntisickling AgentsCerebrovascular DisordersHydroxyureaAdolescentChildChild, PreschoolFemaleHumansInfantMaleNational Heart, Lung, and Blood Institute (U.S.)Practice Guidelines as TopicRetrospective StudiesUnited StatesAntisickling AgentsHydroxyureaHydroxyureasickle cell disease (SCD)silent cerebral infarct (SCI)stroketranscranial Doppler ultrasound (TCD)

Identifiers

PMID41388752
PMCPMC12928155

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.